Home / Conditions / Obesity (page 2)

Obesity

Obesity and Diabetes: Diabetes patients are considered obese when they have a Body Mass Index over 30. Such patients are at greater risk for a host of other problems cardiovascular disease, cancer, sleep apnea, and poor quality of life. Tremendous research is being done to control, manage, and reverse obesity in diabetics and the educated healthcare professional can help.

The Risk Factor Responsible for Half of America’s Diabetes Cases

Jun 19, 2021 Articles, Obesity, Type 2 Diabetes

Approximately 30% to 53% of diabetes mellitus cases in the United States can be attributed to obesity.

Doubling the Dose of Semaglutide for Weight Loss Approved

Jun 12, 2021 Articles, GLP-1 Agonist Therapy Center, Obesity, Paid

The new approval of Wegovy™ is for a current medication, semaglutide, but more than doubling the standard dose for diabetes treatment.

Tirzepatide Outperforms Insulin Glargine in HbA1c and Weight Loss

Jun 12, 2021 Articles, GLP-1 Agonist Therapy Center, Obesity, Type 2 Diabetes

SURPASS-4 is a randomized controlled trial of tirzepatide once a week vs. insulin glargine once a day in type 2 diabetes patients with high cardiovascular risk.

Bariatric Surgery and Cardiovascular Disease

Jun 12, 2021 Articles, Cardiology, Obesity, Surgery

A study aims to establish whether bariatric surgery can reduce adverse cardiovascular events.

Adiposity and Fat Distribution Impact on Hypertension, Cholesterol, and Diabetes

Jun 1, 2021 Articles, Cardiology, Obesity, Paid, Type 2 Diabetes

Central adiposity shows varying effects on blood pressure, LDL cholesterol, and glycemic profile.

Tirzepatide a Potential Drug for Weight Loss

Jun 1, 2021 Articles, GLP-1 Agonist Therapy Center, Obesity, Type 2 Diabetes

Novel dual GIP and GLP-1 receptor agonist showed promising results for both reduction in A1C and weight loss.

Doubling the Semaglutide Dose Improves Weight Loss

May 25, 2021 Articles, GLP-1 Agonist Therapy Center, Obesity, Paid

Lifestyle management and intervention alongside a once-weekly semaglutide dose of 2.4 mg. can lead to improved weight loss for patients with overweight or obesity.